secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001326190-26-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune ends FY2025 with $274M cash; FDA breakthrough for MASH; Phase 3 planned 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments: $274M at Dec 31, 2025; ~$340M after $75M offering and $8M ATM in Jan 2026.
- FY2025 net loss $88.1M ($1.00/share); Q4 net loss $27.4M ($0.27/share).
- Pemvidutide granted FDA Breakthrough Therapy Designation for MASH; Phase 3 trial planned in 2026.
- Topline data from RECLAIM Phase 2 trial in alcohol use disorder expected Q3 2026.
- Jerry Durso appointed CEO; previously CEO of Intercept Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000013/0001326190-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000013/alt-20260305x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer